Wayne Winegarden – A Flawed Analysis on Valuing Medicines
April 05, 2021
The Institute for Clinical and Economic Review (ICER) promotes itself as “the nation’s drug pricing watchdog.” However, as documented in the first of a series of PRI reports, ICER’s cost-effectiveness analyses contain inappropriate methodologies and subjective judgments in determining the value of medicines. In this podcast, PRI senior fellow Wayne Winegarden discusses why ICER’s reports contain biased, inaccurate assumptions.
Listen on these platforms
Print Friendly